Oxaliplatin with raltitrexed and preoperative radiotherapy in T3-T4 extraperitoneal rectal cancer. A dose finding study

Tumori

Volumn 92, Issue 6, 2006, Pages 474-480

  Lupattelli, Marco ^a,b   Bellavita, Rita ^a   Natalini, Giovanni ^a   Giovenali, Paolo ^a   Sidoni, Angelo ^a   Castagnoli, Paolo ^a   Corgna, Enrichetta ^a   Draghini, Lorena ^a   Trippolini, Romano ^a   Aristei, Cynthia ^a  

^a Province of Perugia Fish Fauna Management and Planning Office   (Italy)

^b POLICLINICO MONTELUCE   (Italy)

Author keywords

Neoadjuvant radiotherapy; Oxaliplatin; Raltitrexed; Rectal cancer

Indexed keywords

OXALIPLATIN; RALTITREXED;

ADULT; AGED; ANASTOMOSIS LEAKAGE; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTITIS; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DYSESTHESIA; FEMALE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; PARESTHESIA; PERITONEUM CANCER; PROCTITIS; RECOMMENDED DRUG DOSE; RECTUM CANCER; RECTUM SURGERY; SEPTIC SHOCK; THROMBOCYTOPENIA;

EID: 33846506055     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200602     Document Type: Article

References (45)

1. Heald RJ, Karanjia ND: Results of radical surgery for rectal cancer. World J Surg, 16: 848-857, 1992.
2. Enker WE: Designing the optimal surgery for rectal carcinoma. Cancer, 78: 1847-1850, 1996.
3. Gastrointestinal Tumor Study Group: Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med, 312: 1465-1472, 1985.
4. Gastrointestinal Tumor Study Group: Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol, 10: 549-557, 1992.
5. Douglass HO, Moertel CG, Mayer RJ, Thomas PR, Lindblad AS, Mittleman A, Stablein DM, Bruckner HW: Survival after postoperative combination treatment of rectal cancer. N Engl J Med, 315: 1294-1295, 1986.
6. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Maialliard SA: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med, 324: 709-715, 1991.
7. National Institutes of Health Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA, 264: 1444-1450, 1990.
8. Freedman GM, Coia LR: Adjuvant and neoadjuvant treatment of rectal cancer. Semin Oncol, 22: 611-624, 1995.
9. Capirci C, Polico C, Mandoliti G: Dislocation of small bowel volume within box pelvic treatment fields, using new "up down table" device. Int J Radiat Oncol Biol Phys, 51: 465-473, 2001.
10. Minsky BD, Conti JA, Huang Y, Knopf K: Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. J Clin Oncol, 13: 1409-1416, 1995.
11. Marijnen CA, Glimelius B: The role of radiotherapy in rectal cancer. Eur J Cancer, 38: 943-952, 2002.
12. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess C, Karstens J, Liersch T, Schmidberger H, Raab R: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 351: 1731-1740, 2004.
13. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, MacDonald JS, Haller DJ, Mayer RJ, Gunderson LL, Rich TA: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med, 331: 502-507, 1994.
14. Smalley SR, Benedetti J, Williamson S, Robertson J, Fisher B, Martenson J, Benson AB, Robert M, Cripps C, MacDonald J: Intergroup 0144 - phase III trial of 5-FU-based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV. Proc ASCO, 22: abst.1006, 2003.
15. Rich TA, Shepard RC, Mosley ST: Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol, 22: 2214-2232, 2004.
16. Lupattelli M, Maranzano E, Bellavita R, Tarducci R, Latini R, Castagnoli P, Bufalari A, Corgna E, Pinaglia D, Rossetti R, Ribacchi R, Latini P: Adjuvant radiochemotherapy in high-risk rectal cancer. Results of a prospective non-randomized study. Tumori, 87: 240-248, 2001.
17. Valentini V, Coco C, Cellini N, Picciocchi A, Fares C, Rosetto ME, Mantini G, Morganti AG, Barbaro B, Cogliandolo S, Nuzzo G, Tedesco M, Ambesi-Impiombato F, Cosimelli M, Rotman M: Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response and sphincter preservation in three-year consecutive studies. Int J Radiat Oncol Biol Phys, 51: 371-383, 2001.
18. Touroutoglou N, Pazdur R: Thymidylate synthase inhibitors. Clin Cancer Res, 2: 227-243, 1996.
19. Clarke SJ, Hanwell J, De Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey GT, Judson IR: Phase I trial of ZD 1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumours. J Clin Oncol, 14: 1495-1503, 1996.
20. Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G; the Tomudex Colorectal Cancer Study Group: Final results of a randomized trial comparing "Tomudex" (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol, 7: 961-965, 1996.
21. Cocconi G, Cunningham D, van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM: Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol, 16: 2943-2952, 1998.
22. Harper P: Advanced colorectal cancer (ACC): results from the latest "Tomudex" (raltitrexed) comparative study (abstr). Proc ASCO, 16: 802, 1997.
23. Cunningham D: Mature results from three large controlled studies with raltitrexed ("Tomudex"). Br J Cancer, 77: 15-21, 1998.
24. Teicher BA, Ara G, Chen YN, Recht A, Coleman CN: Interaction of tomudex with radiation in vitro and in vivo. Int J Oncol, 13: 437-442, 1998.
25. James R, Price P, Valentini V: Raltitrexed (Tomudex) concomitant with radiotherapy as adjuvant treatment for patients with rectal cancer: preliminary results of phase I studies. Eur J Cancer, 35: S19-22, 1999.
26. Gambacorta MA, Valentini V, Morganti AG, Mantini G, Miccichè F, Ratto C, Di Miceli D, Barbaro B, Rotondi F, Alfieri S, Doglietto GB, Garcia-Vargas J, De Paoli A, Rossi C, Cellini N: Chemoradiation with raltitrexed (tomudex) in preoperative treatment of stage II-III resectable rectal cancer: a phase II study. Int J Radiat Oncol Biol Phys, 60: 130-138, 2004.
27. Lupattelli M, Maranzano E, Bellavita R, Natalini G, Corgna E, Rossetti R, Trippa F, Mascioni F, Sidoni A, Anselmo P, Buzzi F, Brugia M, Latini P: Raltitrexed and radiotherapy as adjuvant treatment for stage II-III rectal cancer: a feasibility study. Tumori, 91: 498-504, 2005.
28. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG: Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res, 54: 3500-3505, 1994.
29. Pendyla L, Creaven PJ, Shah G: In vitro cytotoxicity studies of oxaliplatin in human tumor cell lines. Proc Am Cancer Res, 32: 410, 1991.
30. Seitz JF, Bennouna J, Paillot B, Gamelin E, Francois E, Conroy T, Raoul JL, Becouarn Y, Bertheault-Cvitkovic F, Ychou M, Nasca S, Fandi A, Barthelemy P, Douillard JY: Multicenter non-randomized phase II study of raltitrexed (tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. Ann Oncol, 13: 1072-1079, 2002.
31. Cascinu S, Graziano F, Ferrau F, Catalano V, Massacesi C, Santini D, Silva RR, Barni S, Zaniboni A, Battelli N, Siena S, Giordani P, Mari D, Baldelli AM, Antognoli S, Maisano R. Priolo D, Pessi MA, Tonini G, Rota S, Labianca R: Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer: a phase 11 study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol, 13: 716-720, 2002.
32. Scheithauer W, Kornek GV, Schuell B, Ulrich-Pur H, Penz M, Raderer M, Lang F, Schneeweiss B, Lenauer A, Depisch D: Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. Ann Oncol, 12: 709-714, 2001.
33. ICRU report 50: Prescribing, recording and reporting photon beam therapy. International Commission on Radiation Units and Measurements, Bethesda, Maryland, 1993.
34. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
35. Perez CA, Brady LW: Overview. In: Principles and practice of radiation oncology, Perez CA, Brady LW (Eds), 2nd ed, pp 1-62, Lippincott, Philadelphia, 1992.
36. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, Ollivier JM, Bonvalot S, Gignoux M: Pathologic assessment of tumor regression grade after pre-operative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer, 73: 2680-2686, 1994.
37. Bosset JF, Calais G, Daban A, Berger C, Radosevic-Jelic L, Maingon P, Bardet E, Pierart M, Briffaux A: EORTC Radiotherapy Group: Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. Eur J Cancer, 40: 219-224, 2004.
38. Shumate CR, Rich TA, Skibber JM, Ajani JA, Ota DM: Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma: a report of surgical morbidity. Cancer, 7: 3690-3696, 1993.
39. Grann A, Minsky BD, Cohen AM, Saltz L, Guillem JG, Paty PB, Kelsen DP, Kemeny N, Ilson D, Bass-Loeb J: Preliminary results of pre-operative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum, 40: 515-522, 1997.
40. Gambacorta MA, Valentini V, Coco C, Morganti AG, Smaniotto G, Miccichè F, Mantini G, Barbaro B, Garcia-Vargas JE, Magistrelli P, Picciocchi A, Cellini N: Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: phase I and II studies. Int J Radiat Oncol Biol Phys, 60: 139-148, 2004.
41. Freyer G, Bossard N, Romestaing P, Mornex F, Chapet O, Trillet-Lenoir V, Gerard JP: Addition of oxaliplatin to continuous fluorouracil, 1-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. J Clin Oncol, 19: 2433-2438, 2001.
42. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R: Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol, 21: 3098-3104, 2003.
43. Loi S, Ngan SY, Hicks RJ, Mukesh B, Mitchell P, Michael M, Zalcberg J, Leong T, Lim-Joon D, Mackay J, Rischin D: Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial. Br J Cancer, 92: 655-661, 2005.
44. Aschele C, Friso ML, Pucciarelli S, Lonardi S, Sartor L, Fabris G, Urso EDL, Del Bianco P, Sotti G, Lise M, Monfardini S: A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol, 16: 1140-1146, 2005.
45. Vecchio FM, Valentini V, Minsky BD, Padula GD, Venkatraman ES, Balducci M, Micciche F, Ricci R, Morganti AG, Gambacorta MA, Maurizi F, Coco C: The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys, 62: 752-760, 2005.